A randomized phase II trial comparing epirubicin, cisplatin, and capecitabine versus the combination of epirubicin, cisplatin, and capecitabine with pravastatin in patients with irresectable or metastatic gastric carcinoma
Completed
- Conditions
- Gastric carcinomaCancerMalignant neoplasm of stomach
- Registration Number
- ISRCTN23062732
- Lead Sponsor
- Erasmus Medical Center, Department of Medical Oncology (Netherlands)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 43
Inclusion Criteria
1. Histologically proven, irresectable gastric adenocarcinoma, except carcinoma of the cardia
2. WHO 0-2
3. Ability to swallow
4. Adequate hepatic, renal and bone marrow function
Exclusion Criteria
1. Prior chemotherapy or radiotherapy
2. Current treatment with HMG-CoA-reductase inhibitor
3. Peripheral neurotoxicity grade >2
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method